New & Improved!

Submit a New & Noteworthy
April 2018
Response to Market Shortages
By: QuVa Pharma, Inc

As an emerging leader in 503B compounding outsourcing, QuVa Pharma has responded to market demands with increased capability and capacity. Its cGMP ability to produce sterile-to-sterile and API-to-sterile products increases available, safe options for health care providers during times of chronic shortages. QuVa Pharma now has three FDA-registered 503B sterile compounding facilities (two in Texas
and one in New Jersey), and an anticipated 90,000 square-feet of additional space as of Q4 2018.

Click here to view product detail on Findit.

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

    Just answer the following quick question for your chance to win:

    To continue, you must either login or register:

    As of May 24, 2018,'s Terms of Use and Privacy Policy have been updated.
    You can review the Terms of Use HERE and the Privacy Policy HERE.
    By continuing to use, you are agreeing to these changes.